India Quarterly Results BSE NSE Announcements — May 25, 2026

AARTIPHARM : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 18, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026, To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026

Consider and approve Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year Ended 31St March, 2026

To consider and approve the audited financial results for the period ended March 31, 2026 and final dividend, if any

To consider and approve the financial results for the quarter and year ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve, inter alia, the Audited Standalone and Consolidated Financial Results (AFRs) for the quarter and financial year ended March 31, 2026.

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the standalone and consolidated financial results for the period ended March 31, 2026 and increase in authorised share Capital of the Company and alteration to capital clause of the Memorandum of Association of the Company.

To consider and approve the financial results for the period ended March 31, 2026, dividend and Fund Raising

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the audited financial results for the year ended March 31, 2026 and dividend, if any for the year 2025-26

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the audited financial statement for the quarter/year ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026, dividend and buyback for equity shares

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the Audited Standalone and Consolidated Financial Results and Statements of the Company for the quarter and financial year ended on March 31, 2026, and to take on record the Statutory Auditor s Report thereon.

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026, Recommending Dividend, If any, for the Financial year ended 31.03.2026; Considering any other Business Matters.

The Company has informed the Exchange that the meeting of Board of Directors of the ompany to be held on May 20, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026 :To consider and approve the audited financial results for the quarter and year ended March 31, 2026 To consider and recommend final dividend for financial year 2025-26

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and The recommendation of the Final Dividend, if any, for the Financial Year 2025-26

To consider and approve the audited financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the quartely and yearly financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve along with other business items, the following: 1. Audited financial results (standalone) for the quarter and Financial year ended March 31, 2026 along with Statutory Auditors Audit Report thereon. 2. Audited financial results (consolidated) for the quarter Financial year ended March 31, 2026 along with Statutory Auditors Audit Report thereon. Further, the Trading Window for dealing in the shares of the Company in pursuance of Company's Insider Trading Code, shall remain closed till 48 hours after the announcement of the above said financial results of the Company.

Intimation of Board Meeting (i) To consider Audited Standalone and Consolidated Financial Results for the Quarter and financial year ended March 31, 2026 (FY 2025-26); and (ii) Recommendation of Final Dividend (if any) for the FY 2025-26.

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and approve the Pace Digitek Limited Employee Stock Option Plan ( PDL ESOP 2026 )

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026Sub.: Intimation of Board Meeting under Reg.29 of SEBI (LODR) Regulations, 2015.This is to inform and intimate that a meeting of the Board of Directors of Prajay Engineers Syndicate Limited ( The Company ) will be held on Monday, the 25th day of May, 2026, at 04:30 p.m. at the Registered Office situated at 1-10-63 & 64, 5th Floor, Prajay Corporate House, Chikoti Gardens, Begumpet, Hyderabad- 500016, Telangana, India, inter-alia to:1. To consider and approve the Audited Financial Results (both Standalone and Consolidated) for the Quarter and Financial Year ended 31-03-2026 and Balance Sheet and Profit & Loss Account as on that date.This intimation is being submitted pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, in accordance with Code of internal procedures and conduct of the Company for regulating, monitoring and reporting of trading by designated persons framed and adopted in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time), the trading window for dealing in securities of Company by the designated persons was closed from 01st April, 2026 and shall continue to remain closed till 48 hours after the financial results for the Quarter and Financial Year ended 31-03-2026 are declared to the Stock Exchange(s). Kindly take the above information on your records.

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

RVNL : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 21, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026, To consider and approve the financial results for the period ended March 31, 2026 and to recommend dividend

RSL : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 21, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026, To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026 and Final dividend FY 2025-26

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

SEPC Ltd has informed the exchange that the meeting of the board of directors of the company is scheduled on 25/05/2026, inter alia, to consider and approve Audited Standalone and Consolidated Financial Results for Quarter and Financial Year ended March 31, 2026

RAMANEWS : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 19, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026, To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026- Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To consider and approve the financial results for the quarter and year ended March 31, 2026 and consider recommendation of dividend for the year ended March 31, 2026.

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026, dividend and Fund Raising

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend

1. To consider and approve the Audited financial results of the Company for the quarter and year ended March 31, 2026.2. Extension of redemption period of 5% Non-Cumulative Redeemable Preference Shares and 10% Cumulative Redeemable Preference Shares.3. Any other business with the permission of the Chair.

To consider and approve the audited financial results for the period ended March 31, 2026 and final dividend, if any

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

To consider and approve Audited Financial Results for the Quarter and Financial Year (FY) Ended 31St March 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2026

To consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

To consider and approve the Audited Standalone and Consolidated Financial Statements for the quarter and year ended March 31, 2026.

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and other business matters

To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended on March 31, 2026.

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

To consider and approve the financial results for the period ended March 31, 2026 and dividend